J Incl Phenom Macrocycl Chem (2011) 71:435–444
443
5. Lowe, M.P., Parker, D., Reany, O., Aime, S., Botta, M., Castel-
lano, G., Gianolio, E., Pagliarin, R.: pH-dependent modulation of
relaxivity and luminescence in macrocyclic gadolinium and
europium complexes based on reversible intramolecular sulfon-
amide ligation. J. Am. Chem. Soc. 123, 7601–7609 (2001)
6. Zhang, S., Wu, K., Sherry, A.D.: A novel pH-sensitive MRI
contrast agent. Angew. Chem. Int. Ed. 38, 3192–3194 (1999)
7. Aime, S., Ascenzi, P., Comoglio, E., Fasano, M., Paoletti, S.:
Molecular recognition of r-states and t-states of human adult
hemoglobin by a paramagnetic Gd(III) complex by means of the
measurement of solvent water proton relaxation rate. J. Am.
Chem. Soc. 117, 9365–9366 (1995)
8. Giardiello, M. Lowe, M. P., Botta, M.: An esterase-activated
magnetic resonance contrast agent. Chem. Commun. 4044-4046
(2007)
9. Giardiello, M., Lowe, M.P.: Luminescence study of Eu(III)
analogues of esterase-activated magnetic resonance contrast
agents. Inorg. Chem. 48, 8515–8522 (2009)
[Gd(TTDA)(H2O)]2- derivatives. Inorg. Chem. 50, 1275–1287
(2011)
26. Lauffer, R.B., Parmelee, D.J., Ouellet, H.S., Dolan, R.P., Sajiki,
H., Scott, D.M., Bernard, P.J., Buchanan, E.M., Ong, K.Y., Ty-
eklar, Z., Midelfort, K.S., McMurry, T.J., Walovitch, R.C.: MS-
325: A small-molecule vascular imaging agent for magnetic
resonance imaging. Acad. Radiol. 3, S356–S358 (1996)
27. Lauffer, R.B., Parmelee, D.J., Dunham, S.U., Ouellet, H.S., Do-
lan, R.P., Witte, S., McMurry, T.J., Walovitch, R.C.: MS-325:
Albumin-targeted contrast agent for MR angiography. Radiology
207, 529–538 (1998)
28. Parmelee, D.J., Walovitch, R.C., Ouellet, H.S., Lauffer, R.B.:
Preclinical evaluation of the pharmacokinetics, biodistribution,
and elimination of MS-325, a blood pool agent for magnetic
resonance imaging. Invest. Radiol. 32, 741–747 (1997)
29. Caravan, P., Cloutier, N.J., Greenfield, M.T., McDermid, S.A.,
Dunham, S.U., Bulte, J.W.M., Amedio, J.C., Looby, R.J., Sup-
kowski, R.M., Horrocks, W.D., McMurry, T.J., Lauffer, R.B.:
The interaction of MS-325 with human serum albumin and its
effect on proton relaxation rates. J. Am. Chem. Soc. 124,
3152–3162 (2002)
10. Surman, A.J., Bonnet, C.S., Lowe, M.P., Kenny, G.D., Bell, J.D.,
´
Toth, E., Vilar, R.: A pyrophosphate-responsive gadolinium(III)
MRI contrast agent. Chem. Eur. J. 17, 223–230 (2011)
11. Li, W., Parigi, G., Fragai, M.: Luchinat C., Meade, T J.: Mech-
anistic studies of a calcium-dependent MRI contrast agent. Inorg.
Chem. 41, 4018–4024 (2002)
12. Lowe, M.P.: MRI Contrast agents: the next generation. Aust.
J. Chem. 55, 551–556 (2002)
13. Banci, L., Bertini, I., Luchinat, C.: Nuclear and Electron Relax-
ation. VCH, Weinheim (1991)
14. Aime, S., Botta, M., Fasano, M., Terreno, E.: Lanthanide(III)
chelates for NMR biomedical applications. Chem. Soc. Rev. 27,
19–29 (1998)
15. Kroft, L.J.M.: de Roos, A.: Blood pool contrast agents for car-
diovascular MR imaging. J. Magn. Reson. Imaging 10, 395–403
(1999)
16. Clarkson, R.B.: Blood Pool MRI Contrast Agents: Properties and
Characterisation Top. Curr. Chem. 221, 201–235 (2002)
17. Arlart, I.P., Bongartz, G.M., Marchal, G.: Magnetic Resonance
Angiography, 2nd edn. Springer, Berlin (2002)
18. Curry, S., Mandelkow, H., Brick, P., Franks, N.: Crystal structure
of human serum albumin complexed with fatty acid reveals an
asymmetric distribution of binding sites. Nat. Struct. Mol. Biol. 5,
827–835 (1998)
19. Peters, T.J.: All About Albumin: Biochemistry, Genetics and
Medical Applications. Academic Press, San Diego (1996)
20. Curry, S., Brick, P., Franks, N.P.: Fatty acid binding to human
serum albumin: new insights from crystallographic studies. Bio-
chim. Biophys. Acta, Mol. Cell Biol. Lipids 1441, 131–140 (1999)
21. Lauffer, R.B.: Targeted relaxation enhancement agents for MRI.
Magn. Reson. Med. 22, 339–342 (1991)
30. Caravan, P., Comuzzi, C., Crooks, W., McMurry, T.J., Choppin,
G.R., Woulfe, S.R.: Thermodynamic stability and kinetic inert-
ness of MS-325, a new blood pool agent for magnetic resonance
imaging. Inorg. Chem. 40, 2170–2173 (2001)
31. Rapp, J.H., Wolff, S.D., Quinn, S.F., Soto, J.A., Meranze, S.G.,
Muluk, S., Blebea, J., Johnson, S.P., Rofsky, N.M., Duerinckx,
A., Foster, G.S., Kent, K.C., Moneta, G., Middlebrook, M.R.,
Narra, V.R., Toombs, B.D., Pollak, J., Yucel, E.K., Shamsi, K.,
Weisskoff, R.M.: Aortoiliac occlusive disease in patients with
known or suspected peripheral vascular disease: Safety and effi-
cacy of gadofosveset-enhanced MR angiography—Multicenter
comparative phase III study. Radiology 236, 71–78 (2005)
32. Caravan, P.: Protein-targeted gadolinium-based magnetic reso-
nance imaging (MRI) contrast agents: design and mechanism of
action. Acc. Chem. Res. 42, 851–862 (2009)
33. Zech, S.G., Eldredge, H.B., Lowe, M.P., Caravan, P.: Protein
binding to lanthanide(III) complexes can reduce the water
exchange rate at the lanthanide. Inorg. Chem. 46, 3576–3584
(2007)
34. Dumas, S., Jacques, V., Sun, W.-C., Troughton, J.S., Welch, J.T.,
Chasse, J.M., Schmitt-Willich, H., Caravan, P.: High relaxivity
magnetic resonance imaging contrast agents part 1 impact of
single donor atom substitution on relaxivity of serum albumin-
bound gadolinium complexes. Invest. Radiol. 45, 600–612 (2010)
35. Jacques, V., Dumas, S., Sun, W.-C., Troughton, J.S., Greenfield,
M.T., Caravan, P.: High-relaxivity magnetic resonance imaging
contrast agents Part 2 optimization of inner- and second-sphere
relaxivity. Invest. Radiol. 45, 613–624 (2010)
22. Parac-Vogt, T.N., Kimpe, K., Laurent, S., Vander Elst, L., Bur-
tea, C., Chen, F., Muller, R.N., Ni, Y., Verbruggen, A., Binne-
mans, K.: Synthesis, characterization, and pharmacokinetic
evaluation of a potential MRI contrast agent containing two
paramagnetic centers with albumin binding affinity. Chem. Eur. J.
11, 3077–3085 (2005)
23. Aime, S., Gianolio, E., Longo, D., Pagliarin, R., Lovazzano, C.,
Sisti, M.: New insights for pursuing high relaxivity MRI agents
from modelling the binding interaction of Gd-III chelates to HSA.
ChemBioChem 6, 818–820 (2005)
24. Avedano, S., Tei, L., Lombardi, A., Giovenzana, G. B., Aime, S.,
Longo, D.,Botta, M.: Maximizing the relaxivity of HSA-bound
gadolinium complexes by simultaneous optimization of rotation
and water exchange. Chem. Commun. 4726–4728 (2007)
25. Chang, Y.-H., Chen, C.-Y., Singh, G., Chen, H.-Y., Liu, G.-C.,
Goan, Y.-G., Aime, S., Wang, Y.-M.: Synthesis and physico-
chemical characterization of carbon backbone modified
36. Ramage, R., Hopton, D., Parrott, M.J., Kenner, G.W., Moore,
G.A.: Phosphinamides—a new class of amino protecting groups
in peptide-synthesis. J. Chem. Soc. Perkin Trans. 1 6, 1357–1370
(1984)
37. Osborn, H.M.I., Cantrill, A.A., Sweeney, J.B.: Howson, W.:
Direct preparation of n-diphenylphosphinoyl aziridines from 1,
2-aminoalcohols utilizing nucleofugacity of diphenylphosphi-
nates. Tetrahedron Lett. 35, 3159–3162 (1994)
38. Cantrill, A.A., Osborn, H.M.I., Sweeney, J.B.: Preparation and
ring-opening reactions of N-diphenylphosphinyl aziridines. Tet-
rahedron 54, 2181–2208 (1998)
39. Hamblin, J., Abboyi, N., Lowe, M. P.: A binaphthyl-containing
Eu(III) complex and its interaction with human serum albumin: a
luminescence study. Chem. Commun. 657–659 (2005)
40. Aime, S., Botta, M., Fasano, M., Terreno, E.: Paramagnetic Gd-
III-Fe-III heterobimetallic complexes of dtpa-bis-salicylamide.
Spectrchim. Acta 49A, 1315–1322 (1993)
123